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Reliable Methods to Evaluate the Burden of Actinic
Keratoses
Debra Atkins1, Ran H. Bang2, Maya R. Sternberg3 and Suephy C. Chen4,5
Dermatologists treat actinic keratoses to prevent non-melanoma skin cancer. Evaluation of actinic keratosis
therapy depends on reliable measures of the lesions. The commonly used method of directly counting all
visible lesions has been shown to be unreliable. We performed a prospective, single-blinded study to explore
the reliability of body surface area involvement and direct counting of lesions measuring greater than 0.5 cm.
Consecutively available subjects with 42% body surface area involvement of both upper extremities were
recruited from the Albuquerque, NM Veterans Administration Dermatology Clinic upon their arrival. Blinded
investigators evaluated 37 subjects during two visits, baseline and 2 weeks later, using both methods. Data were
analyzed using the 26 pairs where evaluating physician was the same at both time points. Both methods
correlated well when comparing the two time points. Our results did not change when we added the pairs
where the evaluating physician differed in the two time points. Our study demonstrates that both methods are
viable ways to evaluate actinic keratoses, even when the investigators differ at different time points, a practical
matter in clinical trials. Our study provides a promising option to evaluate emerging new actinic keratoses
therapies. However, given that the method was only tested on upper extremities of a veteran population, further
testing must be performed in different anatomical locations and in non-veteran populations.
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INTRODUCTION
Reliability is defined as the extent to which the same
measurements of individuals obtained under different condi-
tions yield the same results (Everitt, 1995). Diagnostic clinical
exams need to be reliable in order to be used in preventive
medicine, in order to obtain the correct diagnosis, make
therapeutic decisions, and obtain data for evidence-based
medicine.
Non-melanoma skin cancer (NMSC) is the most common
cancer in the United States (Miller and Weinstock, 1994);
although mortality from NMSC is rare, there is significant
morbidity associated with the natural course and treatment of
NMSC. Thus, prevention of NMSC, or the treatment of its
precursor lesion, actinic keratoses (AKs), is necessary (Drake
et al., 1995). Evaluation of AK therapy depends on reliable
measures of AKs. One method commonly used is the direct
counting of all visible lesions. Weinstock et al. (2001)
evaluated this method and reported poor reliability in the
direct counting of AKs, even after giving instructions to the
evaluators. After allowing for joint discussion among the
evaluators about discrepancies, substantial variation re-
mained. Problems in this study with the direct counting
approach may reside in difficulty in dealing with small,
almost contiguous, lesions; some evaluators may have
counted each small lesion, whereas others may have
combined them. In light of this finding, we designed and
performed a prospective, single-blinded study to explore the
reliability of more clinically objective measurements of these
AKs. We investigated two methods: body surface area (BSA)
involvement and direct counting (CT) of larger lesions.
RESULTS
Subjects were recruited from May to October of 2001. A total
of 42 subjects were eligible of which five refused to
participate. Subjects reported multiple reasons for refusal,
with distance to travel to and transportation issues being the
most common (n¼3). Thus, a total of 37 subjects were
enrolled in the study. Of note, although our sample size for
the reliability study was determined to be 20 patients, we
recruited more because of other study objectives, not
reported here. Also, 11 of the patients were observed by
different investigators at the two time points, leaving only 26
patients observed by the same investigator. At baseline,
physician A rated 17 patients and physician B rated the
remaining 20 patients. After 2 weeks, physician A re-assessed
11 of their original 17 patients, with the remaining six
patients being re-assessed by physician B. Of physician B’s
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20 patients, only 15 were re-assessed by physician B using
both methods, and the remaining five patients were re-
assessed by physician A.
The overall mean age was 74.0 (SD 8.16) years and only
one subject was a female. Reliability was determined using
data where the evaluating physician was the same at both
time points. Both the BSA and CT methods correlate highly
when comparing the two time points (Table 1).
DISCUSSION
Reliability or precision of a clinical exam in the setting of AK
evaluation is paramount. Our study has investigated both the
BSA method and counting lesions greater than 0.5 cm to
evaluate AKs in the upper extremities of the veteran
population. While investigators attempt for correlation
coefficients to be X0.7 (as seen in the CT results), a value
between 0.40 and 0.75 indicates fair to good reproducibility
(as seen in the BSA results) (Rosner, 1995). Of note, as
expected with the positive and moderate strength reliability,
there were no significant differences in the means by way of
paired t-tests. Thus, because of emerging new therapies for
AKs and early NMSC, our study has potential to provide one
option to evaluate such therapies.
Our study has addressed the methodological issues related
to reliability testing. We blinded the investigators during the
second time point to the baseline results in order to reduce
the chances of bias. We chose 2 weeks between baseline and
the second time point to reduce the chance that the
investigators could remember their baseline answers, but at
the same time to limit the chance of the progression of the
lesions, thereby changing the clinical appearance. Pictures
and digital images were considered early in the study design
to maximize intraobserver data collection. However, diffe-
rences between actual lesions (often made by touching the
lesion) and pictures could influence the reliability estimates.
Our primary analysis was for those pairs where the raters
were the same at the two time points. However, we also
performed an analysis where the raters differed in the two
time points and found an equally robust correlation
coefficient, a practical matter for clinical trials.
Our study has potential limitations. One of the blinded
investigators is a former trainee of the other blinded
investigator. Thus, their approach to evaluating AKs may be
highly correlated, independent of the evaluation method.
Hence, our results may be limited in its general applicability.
We recommend that investigators who wish to use these
methods ensure that blinded evaluators be trained before
their study. Investigators may also wish to evaluate the
agreement between individuals of unrelated training experi-
ence. Another limitation is that our results, using arms, may
not be generalizable to other body parts such as the face.
Similarly, we did not test our methods in other population
such as non-veterans and the organ transplant patients. Thus,
the two methods must be tested in other anatomical locations
and populations before application in these scenarios.
A final consideration is that experts in AK therapies have
argued that lesion counting is an artificial evaluation method
and that the better and more clinically relevant approach is to
look at the number of individual persons cleared of their AKs
(Hywell Williams, personal communication, 2000 EDEN-
IDEA meeting). We recognize that the BSA and CT methods
may not be the most meaningful metrics for the practicing
physician. Moreover, our methods do not address the amount
of actinic damage present in the upper extremity of subjects.
Often actinic damage is present without frank AK lesions.
However, in clinical trials, the severity of visible disease
must be taken into account in order for the results to be
meaningful. In the ‘‘persons-cleared’’ method, neither quanti-
tative nor qualitative accounting of lesion severity takes
place. A person with very few AKs could not be distinguished
from a person with many AKs. Thus, although the BSA and CT
methods may not be the most relevant measures for the
practicing physician, they provide the means to measure AK
severity for clinical trials by providing reliable accounting of
visible AK lesions.
A similar argument may be made in that the CT method is
not representative of the total burden of AK lesions, as only
those lesions greater than 0.5 cm are counted. The CT method
would inadequately represent those patients with few large
AKs but with many small AKs that would constitute a
significant body surface involvement. Thus, the CT method
needs to be accompanied by the BSA method if the total
burden is of interest. If accounting for target lesions is the
outcome measure of choice, then the CT method can be used
alone.
Although we have focused on the reliability of our
methods, we can also comment on the validity of our
methods. In other words, our method applies to AKs and not
just keratotic lesions that mimic AKs, such as verrucae.
Although we did not prove that the lesions that the raters
were evaluating were truly AKs by histology, we have other
proxy measures that are sufficient. Firstly, the raters in our
study were board-certified dermatologists, so we are con-
fident of their ability to clinically diagnose AKs. Secondly, we
Table 1. Body surface area (BSA) and counting lesions greater than 0.5 cm (CT) methods for both arms, at baseline
and 2-week visits for same physician pairs using intraclass and Pearson’s correlation coefficient (N=26)
Measure Mean (SD) Pearson’s correlation coefficient (95% CI) Intraclass correlation coefficient (95% CI)
BSA R+L arm Baseline (time 1) 8.93 (1.62) 0.49 (0.12, 0.73) 0.47 (0.11, 0.72)
2 weeks (time 2) 9.29 (2.29)
CT R+L arm Baseline (time 1) 1.46 (1.79) 0.70 ( 0.41, 0.85) 0.67 (0.38, 0.83)
2 weeks (time 2) 1.42 (2.56)
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treated these lesions with both cryotherapy and topical
5-flurouracil in Phase II of our study (Atkins et al., 2003). The
lesions responded to the therapies, which further confirm
accurate diagnosis.
In conclusion, we have found promising AK measures, the
BSA and CT methods, which address both the size and
numbers of AKs, in a clinical setting. Given the data from
Weinstock et al. (2001), demonstrating the unreliability of
counting all AK lesions, we refined the technique by counting
only lesions greater than 0.5 cm. Our study established, based
on the correlation coefficients, that both the BSA and CT
methods are reliable when the raters are the same as well as
when they are different. We advocate for further testing of the
two methods, particularly in other patient populations,
anatomical areas, and when raters come by different training
pathways.
MATERIALS AND METHODS
We obtained approval for our protocol from the Investigative Review
Board at the New Mexico Veterans Administration Health Care
System and consent from subjects as prescribed by the Investigative
Review Board. Consecutively available subjects with 42% BSA AK
involvement of both upper extremities were recruited from the
Albuquerque, NM Veterans Administration Dermatology Clinic
upon their arrival. Subjects were excluded if they had evidence of
immuunosuppression (ie immunosuppressive medications for organ
transplantation, cancer, or HIV), basal cell nevus syndrome, arm
amputation, or AK treatment on either arm within the past 3 months.
The first two exclusion criteria were chosen because of the
potentially more aggressive biological behavior of AKs in these
scenarios.
The inclusion criteria of 42% BSA involvement of upper
extremities was determined visually, whereas a written question-
naire was administered to evaluate the exclusion criteria. Once
eligibility was determined, participants were instructed not to talk
about the counting methods while the blinded investigators were in
the room or while in close proximity to control observer agreement.
Investigators did not have access to the questionnaire or any medical
forms that contained the clinical data obtained for this study.
The blinded investigators evaluated both upper extremities of
subjects during two visits, baseline and 2 weeks later. For the first
method, blinded investigators counted the number of AK lesions
measuring 40.5 cm (CT method) (Figure 1). The investigators
approximated the size of the lesion, but were allowed to use rulers
for this measurement if needed. The second method (Figure 1)
involved measuring the affected BSA (BSA method) using the rule of
nines (Shuter and Aslani, 2000). This procedure is based upon the
principle of dividing the total BSA into 9% for the head and neck,
each arm, the front and back of each leg, and the four trunk
quadrants, with 1% for the genitalia. This procedure allows for the
subject’s palm width to account for 1% BSA, as the palm would be
self-scaling to the subject. Thus, in our study, each subject had a
possible BSA of 2% (entry criteria) to 18%. To further decrease the
variation in upper extremity BSA estimation, the blinded investi-
gators were trained in this technique before starting the study. In the
study, investigators compared their palm size to that of the subject. If
the sizes were approximately equal, then the investigators used their
own palms. If the subject’s palms were significantly larger or smaller
than that of the investigator, the difference was factored into the
investigator’s measurements. The investigator then surveyed the skin
involved with AKs and mentally ‘‘scooped’’ the lesions together into
non-overlapping plaques. These plaques were measured using the
investigator’s palm. Training was performed by verbal instruction by
the principal investigator (SC) through the coordinator. AKs were
defined as erythematous scaly papules or plaques. However, if a lesion
was not particularly erythematous or scaly, and the clinician still felt
that it was consistent with an AK, they were allowed to include it.
Study design
Left and right arms of eligible subjects were assessed by the two
different methods (BSA and CT) at baseline and subse-
quently at 2 weeks. There were two different physicians, A and B.
Owing to logistical reasons, the same physician did not necessarily
see the same patient at 2 weeks. We present the analysis of the
subset of patients who were examined by the same physician at
baseline and 2 weeks. For robustness of the conclusions, all patients
were then analyzed together; however, details of this latter analysis
are not included.
Analyses
We calculated our sample size to be 20 subjects, which would allow
us to detect a correlation coefficient of at least 0.70 with 80% power.
To evaluate and compare reliability, we analyzed BSA and CT using
intraclass and Pearson correlation coefficients between the baseline
and the 2-week follow-up visit. We analyzed data where the blinded
investigators were the same at the two time points. Confidence
intervals for the Pearson correlation coefficients were computed
using a Fisher’s transformation. All data were analyzed using the
statistical package SAS (SAS Institute, 2003).
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Figure 1. Illustration of BSA and CT method. The steps of the BSA method
are illustrated through three scenarios. Scenario A represents an upper
extremity with AK lesions, as depicted by the circles and ellipses. Scenario B
represents the ‘‘scooping’’ that the investigator mentally performs, putting all
the lesions together in a non-overlapping manner. Scenario C depicts using
the investigator’s palm to approximate the BSA that the lesions occupy. Each
palm represents 1% BSA. Thus, in our example, there are 214 palms filled with
AK lesions, representing 2.25% BSA. For the CT method, the investigator
counts lesions greater than or equal to 0.5 cm in diameter. If, in our example,
the circles represent lesions with a diameter of 0.25 cm and the ellipses
represent lesions of diameter 0.75 cm (greatest length), then the investigator
would count two lesions by this method.
www.jidonline.org 593
D Atkins et al.
Reliable Methods to Evaluate Actinic Keratoses
ACKNOWLEDGMENTS
We thank Dr Edward Smith for participating as a blinded investigator. This
project was supported in part from an American Skin Association (ASA)
Health Services Research Grant, the ASA David Martin Carter Research
Scholar Award, and an Emory Skin Disease Research Center Pilot and
Feasibility grant (#P30AR42687) from the National Institute on Arthritis and
Musculoskeletal and Skin Disease (NIAMS), National Institutes of Health
(NIH). Dr Chen is supported in part by a Mentored Patient Oriented Career
Development Award (#K23AR02185-01A1) from NIAMS, NIH.
REFERENCES
SAS Institute (2003) SAS version 9.1. Cary, NC: SAS Institute
Atkins D, Moore AM, Vanexel C, Sternberg M, Bang RH, Chen SC (2003)
Actinic keratoses: reliable assessment methods and a comparative trial
between liquid nitrogen and topical 5-flurouracil. Miami Beach, FL:
International Investigative Dermatology
Drake LA, Ceilley RI, Cornelison RL, Dobes WL, Dorner W, Golz RW et al.
(1995) Guidelines of care for actinic keratoses. Committee on Guidelines
of Care. J Am Acad Dermatol 32:95–8
Everitt BS (1995) The Cambridge Dictionary of Statistics in the Medical
Sciences. Cambridge: Cambrdige University Press
Miller DL, Weinstock MA (1994) Nonmelanoma skin cancer in the United
States: incidence. J Am Acad Dermatol 30:774–8
Rosner B (1995) Fundamentals of biostatistics. Boston: ITP publishers
Shuter B, Aslani A (2000) Body surface area: Du Bois and Du Bois revisted.
Eur J Appl Physiol 82:250–4
Weinstock M, Bingham SF, Cole GW, Eilers D, Naylor MF, Kalivas J et al.
(2001) Reliability of counting actinic keratoses before and after brief
consensus discussion: the VA topical tretinoin chemoprevention
(VATTC) trial. Arch Dermatol 137:1055–8
594 Journal of Investigative Dermatology (2006), Volume 126
D Atkins et al.
Reliable Methods to Evaluate Actinic Keratoses
